Daewoong Pet, led by CEOs Hyo-Joon Lee and Jae-Bong Moon, announced on May 27th the launch of the 'UDCA Tablet,' a new pharmaceutical designed to support liver health in pets. The tablet contains the active ingredient ursodeoxycholic acid (UDCA).

Developed specifically for pets, UDCA Tablet is available exclusively through veterinary clinics and contains 200mg of UDCA per tablet. Traditionally, UDCA pharmaceuticals were developed for human use and administered to pets in divided doses, which often resulted in low palatability. Daewoong Pet addressed this issue by creating a chewable form that pets can easily consume, enhancing both convenience and taste.

Pets are susceptible to hepatobiliary diseases due to aging or bacterial infections. Given that pet food is not as strictly regulated as human food, pets are more likely to be exposed to pathogens. This insight led to the development of a product that protects liver cells and improves liver function in dogs and cats with hepatobiliary conditions.

The product's reliability is enhanced by using high-purity, high-quality raw materials from Daewoong Bio, which supplies over 25% of the global UDCA raw material market.

Daewoong Pet aims to solidify its position in the pet market by expanding its product range from health supplements to pharmaceutical products. CEO Hyo-Joon Lee stated, "Even before its launch, UDCA Tablet has garnered significant anticipation and interest from the industry as a pet adaptation of Daewoong Pharmaceutical's core human medicine. We incorporated advice from over 200 industry experts and clinical veterinarians, developing it as a chewable tablet to enhance palatability and allow for standalone prescription or compounding per hospital needs. We will continue to introduce verified effective and safe animal pharmaceuticals to create a safe treatment environment for pets."